TOB1 (Ab-164) Antibody

What is TOB1 protein and what cellular functions does it regulate?

TOB1 (Transducer of ERBB2, 1) functions primarily as an anti-proliferative protein in cellular systems. Its activity is mediated through association with deadenylase subunits of the CCR4-NOT complex, which plays a critical role in mRNA degradation pathways . TOB1 has been demonstrated to act as a potential tumor suppressor by regulating cell growth and proliferation. The protein mediates CPEB3-accelerated mRNA deadenylation by binding to CPEB3 and recruiting CNOT7, which leads to target mRNA deadenylation and decay . This function positions TOB1 as a key regulator in cellular processes related to growth control and potentially in cancer development pathways.

What is the molecular structure and specificity of TOB1 (Ab-164) Antibody?

TOB1 (Ab-164) Antibody is a polyclonal antibody raised in rabbits against a synthesized non-phosphopeptide derived from human TOB1 protein, specifically targeting the region around the phosphorylation site of serine 164 (A-V-S(p)-P-T) . This antibody has been affinity-purified from rabbit antiserum using epitope-specific immunogen chromatography, resulting in high specificity for its target sequence . The antibody is typically supplied in liquid form containing phosphate buffered saline (without Mg²⁺ and Ca²⁺) at pH 7.4, with 150mM NaCl, 0.02% sodium azide, and 50% glycerol . Its molecular design enables recognition of the non-phosphorylated form of TOB1 at the Ser164 position.

Which experimental applications is TOB1 (Ab-164) Antibody validated for?

TOB1 (Ab-164) Antibody has been validated for multiple research applications:

The antibody has demonstrated reliable performance in these applications, with specific reactivity to human and mouse samples . Validation studies have included Western blot analysis of extracts from HT-29 cells treated with serum (20%, 15mins), confirming specific detection of TOB1 .

How should researchers optimize TOB1 (Ab-164) Antibody dilutions for different experimental approaches?

Optimization of TOB1 (Ab-164) Antibody dilutions requires systematic titration based on the specific application:

For Western Blotting:

• Begin with a mid-range dilution (1:1000) using positive control samples (e.g., HT-29 cell lysates treated with serum)

• Perform a gradient dilution series (1:500, 1:1000, 1:2000, 1:3000) to determine optimal signal-to-noise ratio

• Include both phosphorylated and non-phosphorylated controls to confirm specificity

• Optimize blocking conditions with 5% BSA to minimize background

For Immunohistochemistry:

• Start with a 1:75 dilution on known positive tissue sections

• Evaluate multiple antigen retrieval methods (citrate buffer pH 6.0 vs. EDTA pH 9.0)

• Titrate primary antibody incubation time (overnight at 4°C vs. 1 hour at room temperature)

• Include negative controls (secondary antibody only) and isotype controls

These methodological approaches should be documented with standardized protocols to ensure reproducibility across experiments .

What are the critical differences between phospho-specific and non-phospho-specific TOB1 antibodies and when should each be used?

The distinction between phospho-specific and non-phospho-specific TOB1 antibodies represents a critical experimental design consideration:

Researchers should employ non-phospho-specific antibodies (TOB1 Ab-164) when:

• Investigating total TOB1 protein expression levels

• Examining TOB1 localization independent of phosphorylation status

• Normalizing phospho-TOB1 levels against total TOB1

In contrast, phospho-specific antibodies (pSer164) are appropriate when:

• Studying specific signaling events that trigger TOB1 phosphorylation

• Investigating the functional consequences of TOB1 phosphorylation

• Analyzing the dynamic regulation of TOB1 activity in response to stimuli

For comprehensive signaling studies, both antibodies should be used in parallel to determine the phosphorylation ratio (phospho/total TOB1) .

What methodological approaches can distinguish between TOB1 phosphorylation states in complex tissue samples?

Distinguishing between TOB1 phosphorylation states in complex tissue samples requires integrated methodological approaches:

• Sequential Immunoprecipitation Strategy:

  • Initial immunoprecipitation with total TOB1 antibody

  • Division of precipitated sample

  • Western blot analysis with both phospho-specific and non-phospho antibodies

  • Calculation of phosphorylation ratio within the same sample pool

• Phosphatase Treatment Controls:

  • Split tissue lysate into two identical aliquots

  • Treat one aliquot with lambda phosphatase

  • Compare TOB1 detection using both phospho-specific and non-phospho antibodies

  • Confirm phospho-specificity through signal reduction in treated samples

• Quantitative Mass Spectrometry Validation:

  • Immunoprecipitate TOB1 from tissue samples

  • Perform tryptic digestion

  • Analyze peptides containing Ser164 by mass spectrometry

  • Quantify phosphorylated versus non-phosphorylated peptide forms

These complementary approaches provide robust verification of phosphorylation status while addressing the inherent complexity of tissue samples .

How can researchers effectively validate TOB1 (Ab-164) Antibody specificity for their experimental system?

Comprehensive validation of TOB1 (Ab-164) Antibody specificity requires a multi-faceted approach:

• Genetic Validation:

  • CRISPR/Cas9 knockout of TOB1 in relevant cell lines

  • siRNA-mediated knockdown with titrated concentrations

  • Overexpression of TOB1 with epitope tags

  • Western blot comparison between these genetic modifications and controls

• Peptide Competition Assay:

  • Pre-incubate antibody with excess immunizing peptide (A-V-S-P-T)

  • Compare signal between blocked and unblocked antibody

  • Include gradient concentrations of competing peptide (10-100X molar excess)

  • Document signal reduction proportional to peptide concentration

• Cross-Reactivity Assessment:

  • Express TOB1 paralogs (e.g., TOB2) in cellular systems

  • Compare detection between TOB1 and potential cross-reactive proteins

  • Include purified recombinant proteins in dot blot analysis

  • Assess non-specific binding to related BTG family proteins

• Application-Specific Controls:

  • For IHC: Include tissue from TOB1 knockout models

  • For WB: Include molecular weight markers and positive control lysates

  • For all applications: Include secondary-only controls

This systematic validation framework ensures experimental reliability and reproducibility when working with this antibody .

How should researchers address potential data inconsistencies when comparing TOB1 phosphorylation results across different experimental platforms?

Addressing data inconsistencies in TOB1 phosphorylation studies requires systematic methodological reconciliation:

• Platform-Specific Normalization Strategies:

  • Western Blot: Normalize phospho-TOB1 signal to total TOB1 rather than housekeeping proteins

  • IHC: Employ digital image analysis with consistent thresholding algorithms

  • ELISA: Generate standard curves using recombinant phosphorylated and non-phosphorylated TOB1

  • Compare relative changes rather than absolute values across platforms

• Methodological Reconciliation Protocol:

  • Document antibody lot numbers used across experiments

  • Standardize sample preparation (lysis buffers, phosphatase inhibitors)

  • Maintain consistent blocking reagents and incubation conditions

  • Perform spike-in recovery assays to assess matrix effects

• Statistical Approach for Cross-Platform Comparison:

  • Apply Bland-Altman analysis to quantify agreement between methods

  • Calculate correlation coefficients between normalized values

  • Determine platform-specific detection limits and linear ranges

  • Implement multiple comparison corrections for large-scale analyses

By systematically addressing these technical variables, researchers can more confidently interpret TOB1 phosphorylation data across experimental platforms .

What are the implications of different cellular contexts on TOB1 phosphorylation status and antibody detection sensitivity?

The cellular context significantly impacts TOB1 phosphorylation dynamics and detection sensitivity:

Methodological approaches to address these contextual variations should include:

• Temporal Dynamics Analysis:

  • Short-interval time courses after stimulation (e.g., serum treatment)

  • Phosphatase inhibitor optimization for each cell type

  • Parallel analysis of upstream kinase activation

  • Documentation of cell density and passage number

• Signal Pathway Integration:

  • Assess phosphorylation of known upstream regulators of TOB1

  • Pharmacological inhibition of relevant kinase pathways

  • Correlation of TOB1 phosphorylation with functional outcomes

  • Multi-parametric analysis of related signaling nodes

These approaches recognize that TOB1 phosphorylation represents a dynamic process rather than a static state, requiring nuanced interpretation based on cellular context .

How can TOB1 (Ab-164) Antibody be effectively incorporated into multi-parameter analysis of cell proliferation pathways?

Integrating TOB1 (Ab-164) Antibody into multi-parameter proliferation analyses requires coordinated methodological approaches:

• Multiplex Immunofluorescence Protocol:

  • Co-staining of TOB1 with proliferation markers (Ki-67, PCNA)

  • Inclusion of cell cycle markers (Cyclin D1, p27)

  • Addition of upstream pathway components (ERK1/2, AKT)

  • Spectral unmixing for accurate signal discrimination

• Sequential Protein Array Analysis:

  • Reverse Phase Protein Array (RPPA) with TOB1 and phospho-TOB1 antibodies

  • Correlation with 30-50 cell cycle and proliferation markers

  • Hierarchical clustering to identify co-regulated pathways

  • Principal component analysis to determine primary regulatory axes

• Single-Cell Analysis Integration:

  • Flow cytometry with TOB1 and cell cycle markers

  • Imaging flow cytometry for subcellular localization

  • Correlation of TOB1 phosphorylation with DNA content

  • Computational modeling of phosphorylation dynamics

These integrative approaches position TOB1 within its broader signaling context rather than as an isolated marker, enabling systems-level understanding of its role in proliferation control .

What are the methodological considerations for studying TOB1 phosphorylation in relation to its tumor suppressor functions in cancer models?

Studying TOB1 phosphorylation in cancer models requires specific methodological considerations:

• Cancer Type-Specific Baseline Establishment:

  • Analysis of TOB1 expression across cancer types (TCGA database correlation)

  • Comparison between matched normal and tumor tissues

  • Identification of cancer subtypes with altered TOB1 phosphorylation

  • Development of cancer-specific positive controls

• Functional Correlation Protocol:

  • Generate phosphomimetic (S164D) and phospho-deficient (S164A) TOB1 mutants

  • Stable expression in relevant cancer cell lines

  • Measure proliferation, colony formation, and invasion

  • Correlate functional outcomes with phosphorylation status

• In Vivo Translation Strategy:

  • Tissue microarray analysis of human tumors with phospho-TOB1 antibodies

  • Correlation with clinical outcomes and molecular subtypes

  • Xenograft models with phospho-mutant TOB1 expression

  • Therapeutic response correlation with TOB1 phosphorylation status

By implementing these methodological approaches, researchers can establish causal relationships between TOB1 phosphorylation status and its tumor suppressor functions, potentially identifying new therapeutic vulnerabilities in cancer models .

What are the most common technical challenges when using TOB1 (Ab-164) Antibody and how can they be systematically addressed?

Systematic troubleshooting of TOB1 (Ab-164) Antibody applications requires identification of common technical challenges and their corresponding solutions:

Implementation of a standardized troubleshooting protocol includes:

• Systematic Optimization Procedure:

  • Gradient dilution series (1:250, 1:500, 1:1000, 1:2000, 1:3000)

  • Blocking agent comparison (BSA vs. milk vs. commercial blockers)

  • Incubation condition matrix (4°C overnight vs. room temperature 1-2 hours)

  • Secondary antibody titration in parallel

• Antibody Performance Tracking:

  • Maintain control lysate aliquots from a single preparation

  • Document signal-to-noise ratios for each experiment

  • Record lot numbers and performance metrics

  • Implement regular validation checkpoints

These systematic approaches transform troubleshooting from reactive problem-solving to proactive quality control .

How can researchers implement rigorous quality control measures for long-term studies using TOB1 (Ab-164) Antibody?

Long-term studies using TOB1 (Ab-164) Antibody require implementation of comprehensive quality control strategies:

• Reference Standard Protocol:

  • Create large batches of control lysates from relevant cell lines

  • Aliquot and store at -80°C with minimal freeze-thaw cycles

  • Include positive controls (serum-stimulated cells) and negative controls

  • Generate standard curves for quantitative applications

• Antibody Performance Monitoring System:

  • Maintain detailed antibody inventory with lot numbers and receipt dates

  • Document performance metrics for each lot (signal intensity, background)

  • Perform side-by-side comparison when transitioning to new lots

  • Calculate lot-to-lot variation coefficients

• Experimental Validation Checkpoints:

  • Schedule regular validation experiments (monthly or quarterly)

  • Include peptide competition controls periodically

  • Verify antibody specificity against recombinant standards

  • Document all validation results in a centralized repository

• Data Normalization Strategy:

  • Implement statistical process control charts for key parameters

  • Define acceptable variation limits for control samples

  • Apply batch correction algorithms for large datasets

  • Normalize to internal standards rather than between experiments

Implementation of these quality control measures significantly enhances data reliability and facilitates meaningful integration of results collected over extended time periods .